These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 32896220)
1. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know? Zhu J; Pasternak AL; Crona DJ Pharmacogenomics; 2020 Oct; 21(15):1061-1064. PubMed ID: 32896220 [No Abstract] [Full Text] [Related]
2. "What do we know about tacrolimus pharmacogenetics in transplant recipients?". Kuypers DR Pharmacogenomics; 2018 May; 19(7):593-597. PubMed ID: 29701126 [No Abstract] [Full Text] [Related]
3. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients. Kuypers DR Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539 [No Abstract] [Full Text] [Related]
5. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Birdwell KA; Decker B; Barbarino JM; Peterson JF; Stein CM; Sadee W; Wang D; Vinks AA; He Y; Swen JJ; Leeder JS; van Schaik R; Thummel KE; Klein TE; Caudle KE; MacPhee IA Clin Pharmacol Ther; 2015 Jul; 98(1):19-24. PubMed ID: 25801146 [TBL] [Abstract][Full Text] [Related]
7. Editorial: pharmacogenetics and molecular medicine: "so close and yet so far". Moore JH; Hwa J Curr Mol Med; 2014; 14(7):803-4. PubMed ID: 25109800 [No Abstract] [Full Text] [Related]
8. PACE Forward-Making Pharmacogenomics Testing Available for Real-Life Clinical Utility. Lazaridis KN Clin Pharmacol Ther; 2019 Jan; 105(1):42-44. PubMed ID: 30520030 [TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and tacrolimus administration in stem cell transplantation. Patel JN; Hamadeh IS Pharmacogenomics; 2020 Apr; 21(6):419-426. PubMed ID: 32308133 [TBL] [Abstract][Full Text] [Related]
10. Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients. Wang P; Mao Y; Razo J; Zhou X; Wong ST; Patel S; Elliott E; Shea E; Wu AH; Gaber AO Pharmacogenomics; 2010 Oct; 11(10):1389-402. PubMed ID: 21047202 [TBL] [Abstract][Full Text] [Related]
11. Understanding and Preventing Adverse Effects of Tacrolimus Metabolization in Transplant Patients. Fröhlich E Curr Drug Metab; 2019; 20(13):1039-1040. PubMed ID: 30081785 [No Abstract] [Full Text] [Related]
12. Clinical implementation of pharmacogenetics. García-González X; Cabaleiro T; Herrero MJ; McLeod H; López-Fernández LA Drug Metab Pers Ther; 2016 Mar; 31(1):9-16. PubMed ID: 26751902 [TBL] [Abstract][Full Text] [Related]
13. Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome? van Gelder T; Hesselink DA Clin Pharmacol Ther; 2010 Jun; 87(6):640-1. PubMed ID: 20485320 [TBL] [Abstract][Full Text] [Related]
17. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564 [TBL] [Abstract][Full Text] [Related]
18. [Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients]. Zhu L; Song HT; Wang QH; Wu WZ; Yang SL; Tan JM Yao Xue Xue Bao; 2012 Jul; 47(7):878-83. PubMed ID: 22993851 [TBL] [Abstract][Full Text] [Related]